Loading...
56 colchicine COVID-19 controlled studies, 30 RCTs
45% improvement
for early treatment, RR
0.55
[0.18-1.67]
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Hunt
68%
0.32 [0.15-0.67]
death
Improvement, RR [CI]
Treatment
Control
Hassan (RCT)
-40%
1.40 [0.48-4.12]
hosp.
7/50
5/50
Hassan (RCT)
4%
0.96 [0.68-1.37]
no recov.
27/50
28/50
Inokuchi (RCT)
67%
0.33 [0.03-3.29]
hosp.
1/23
2/15
OT1 CT2
Inokuchi (RCT)
24%
0.76 [0.35-1.67]
no recov.
8/21
6/12
OT1 CT2
Inokuchi (RCT)
-17%
1.17 [0.66-2.07]
recov. time
21 (n)
12 (n)
OT1 CT2
GRECCO-19
Deftereos (RCT)
77%
0.23 [0.03-1.97]
death
1/55
4/50
GRECCO-19
Deftereos (RCT)
82%
0.18 [0.02-1.50]
ventilation
1/55
5/50
GRECCO-19
Deftereos (RCT)
87%
0.13 [0.01-0.97]
progression
1/55
7/50
Lopes (DB RCT)
80%
0.20 [0.01-4.03]
death
0/36
2/36
Lopes (DB RCT)
50%
0.50 [0.10-2.56]
ICU
2/36
4/36
Lopes (DB RCT)
22%
0.78 [0.64-0.94]
hosp. time
36 (n)
36 (n)
Brunetti (PSM)
73%
0.27 [0.08-0.89]
death
3/33
11/33
Brunetti (PSM)
73%
0.27 [0.08-0.89]
no disch.
3/33
11/33
Scarsi
85%
0.15 [0.06-0.37]
death
122 (n)
140 (n)
Salehzadeh (RCT)
23%
0.77 [0.66-0.90]
hosp. time
50 (n)
50 (n)
Pinzón
35%
0.65 [0.34-1.21]
death
14/145
23/156
Sandhu
42%
0.58 [0.40-0.85]
death
16/34
63/78
Sandhu
53%
0.47 [0.33-0.67]
ventilation
16/34
68/68
Sandhu
42%
0.58 [0.40-0.85]
no disch.
16/34
63/78
Rodriguez-Nava
6%
0.94 [0.61-1.47]
death
16/52
85/261
Mahale
-7%
1.07 [0.59-1.96]
death
11/39
25/95
Valerio Pas.. (ICU)
23%
0.77 [0.31-1.94]
death
5/35
12/30
ICU patients CT2
Valerio Pas.. (ICU)
40%
0.60 [0.38-0.95]
ICU
35 (n)
30 (n)
ICU patients CT2
COLCORONA
Tardif (DB RCT)
44%
0.56 [0.19-1.67]
death
5/2,235
9/2,253
COLCORONA
Tardif (DB RCT)
20%
0.80 [0.62-1.03]
death/hosp.
104/2,235
131/2,253
COLCORONA
Tardif (DB RCT)
47%
0.53 [0.25-1.09]
ventilation
11/2,235
21/2,253
COLCORONA
Tardif (DB RCT)
20%
0.80 [0.61-1.03]
hosp.
101/2,235
128/2,253
Mareev
80%
0.20 [0.01-4.01]
death
0/21
2/22
Mareev
50%
0.50 [0.24-1.04]
no recov.
21 (n)
22 (n)
Mareev
71%
0.29 [0.13-0.63]
no recov.
21 (n)
22 (n)
Mareev
67%
0.33 [0.10-1.07]
no recov.
21 (n)
22 (n)
Mareev
26%
0.74 [0.53-1.04]
hosp. time
21 (n)
22 (n)
García-Posada
57%
0.43 [0.16-0.84]
death
48/99
59/110
CT2
Manenti (PSW)
76%
0.24 [0.09-0.67]
death
71 (n)
70 (n)
Manenti (PSW)
44%
0.56 [0.31-1.00]
no recov.
71 (n)
70 (n)
Mostafaie (RCT)
83%
0.17 [0.02-1.34]
death
1/60
6/60
CT2
Mostafaie (RCT)
35%
0.65 [0.53-0.81]
hosp. time
59 (n)
54 (n)
CT2
RECOVERY
Recovery C.. (RCT)
-1%
1.01 [0.93-1.10]
death
1,173/5,610
1,190/5,730
RECOVERY
Recovery C.. (RCT)
-18%
1.18 [0.99-1.40]
ventilation
259/3,815
228/3,962
RECOVERY
Recovery C.. (RCT)
-2%
1.02 [0.96-1.09]
death/int.
1,344/5,342
1,343/5,469
RECOVERY
Recovery C.. (RCT)
-2%
1.02 [0.97-1.06]
no disch.
1,709/5,610
1,698/5,730
Hueda-Zavaleta
54%
0.46 [0.23-0.91]
death
10/50
109/301
Kevorkian
96%
0.04 [0.01-0.21]
progression
28 (n)
40 (n)
CT2
Gaitán-Dua.. (RCT)
22%
0.78 [0.44-1.36]
death
22/153
28/161
CT2
Pascual-Fi.. (RCT)
80%
0.20 [0.01-4.03]
death
0/52
2/51
Pascual-Fi.. (RCT)
80%
0.20 [0.01-4.03]
ventilation
0/52
2/51
Pascual-Fi.. (RCT)
51%
0.49 [0.09-2.56]
ICU
2/52
4/51
Pascual-Fi.. (RCT)
87%
0.13 [0.01-0.71]
7-point status
3/52
7/51
Pascual-Fi.. (RCT)
80%
0.20 [0.01-4.03]
7-point status
0/52
2/51
Pascual-Fi.. (RCT)
-15%
1.15 [0.87-1.51]
hosp. time
52 (n)
51 (n)
Dorward (RCT)
70%
0.30 [0.01-7.37]
death
0/156
1/120
Dorward (RCT)
-30%
1.30 [0.42-3.84]
death/hosp.
6/156
4/133
Dorward (RCT)
22%
0.78 [0.30-1.73]
death/hosp.
6/156
119/1,145
Dorward (RCT)
-6%
1.06 [0.81-1.39]
no recov.
156 (n)
133 (n)
Absalón-.. (DB RCT)
29%
0.71 [0.21-2.40]
death
4/56
6/60
Absalón-.. (DB RCT)
17%
0.83 [0.35-1.93]
progression
56 (n)
60 (n)
Absalón-.. (DB RCT)
-13%
1.13 [0.76-1.66]
no recov.
56 (n)
60 (n)
Diaz (RCT)
12%
0.88 [0.70-1.12]
death
131/640
142/639
Diaz (RCT)
17%
0.83 [0.67-1.02]
death/int.
160/640
184/639
Diaz (RCT)
52%
0.48 [0.18-1.27]
death/int.
6/93
13/102
Diaz (RCT)
17%
0.83 [0.64-1.07]
death
98/515
140/634
Diaz (RCT)
25%
0.75 [0.60-0.95]
death/int.
117/515
181/634
Alsultan (RCT)
36%
0.64 [0.20-2.07]
death
3/14
7/21
Karakaş
13%
0.87 [0.46-1.64]
death
16/165
19/171
Karakaş
16%
0.84 [0.55-1.29]
ICU
30/165
37/171
Karakaş
25%
0.75 [0.65-0.87]
hosp. time
165 (n)
171 (n)
Pourdowlat (RCT)
73%
0.27 [0.11-0.71]
hosp.
5/102
18/100
Pourdowlat (RCT)
38%
0.62 [0.41-0.94]
no recov.
89 (n)
63 (n)
Pourdowlat (RCT)
22%
0.78 [0.60-1.00]
no recov.
89 (n)
63 (n)
Gorial (RCT)
67%
0.33 [0.04-3.14]
death
1/80
3/80
Gorial (RCT)
63%
0.37 [0.21-0.67]
no recov.
80 (n)
80 (n)
STRUCK
Pimenta B.. (RCT)
79%
0.21 [0.01-4.05]
death
0/14
2/16
STRUCK
Pimenta B.. (RCT)
85%
0.15 [0.01-2.69]
no improv.
0/14
3/16
Jalal (RCT)
24%
0.76 [0.62-0.93]
hosp. time
36 (n)
44 (n)
Cecconi (DB RCT)
29%
0.71 [0.28-1.79]
death
7/119
10/120
Cecconi (DB RCT)
50%
0.50 [0.18-1.43]
ventilation
5/119
10/120
Cecconi (DB RCT)
21%
0.79 [0.38-1.67]
ICU
11/119
14/120
Cecconi (DB RCT)
15%
0.85 [0.50-1.43]
NIV/ICU/vent./death
21/119
25/120
ACT inpatient
Eikelboom (RCT)
-8%
1.08 [0.91-1.29]
death
264/1,304
249/1,307
ACT inpatient
Eikelboom (RCT)
-4%
1.04 [0.90-1.21]
progression
368/1,304
356/1,307
ACT inpatient
Eikelboom (RCT)
2%
0.98 [0.82-1.17]
progression
246/1,304
252/1,307
ACT outpatient
Eikelboom (RCT)
-9%
1.09 [0.48-2.47]
death
12/1,939
11/1,942
ACT outpatient
Eikelboom (RCT)
-2%
1.02 [0.72-1.43]
death/hosp.
66/1,939
65/1,942
ACT outpatient
Eikelboom (RCT)
-2%
1.02 [0.71-1.45]
hosp.
62/1,939
61/1,942
COLVID-19
Perricone (RCT)
-36%
1.36 [0.45-4.11]
death
7/77
5/75
COLVID-19
Perricone (RCT)
-7%
1.07 [0.48-2.37]
progression
11/77
10/75
COLVID-19
Perricone (RCT)
-30%
1.30 [0.30-5.61]
ventilation
4/77
3/75
COLVID-19
Perricone (RCT)
76%
0.24 [0.03-2.13]
ICU
1/77
4/75
COLVID-19
Perricone (RCT)
4%
0.96 [0.79-1.17]
hosp. time
77 (n)
75 (n)
Rahman (DB RCT)
71%
0.29 [0.10-0.92]
death
4/146
13/146
Rahman (DB RCT)
71%
0.29 [0.10-0.92]
progression
4/146
13/146
Rahman (DB RCT)
61%
0.39 [0.08-2.02]
death
2/146
5/146
Rahman (DB RCT)
51%
0.49 [0.09-2.68]
ventilation
2/146
4/146
Rahman (DB RCT)
56%
0.44 [0.13-1.43]
progression
4/146
9/146
Hueda-Zavaleta
-33%
1.33 [0.75-2.36]
death
18/52
33/148
Ventilated patients
Kasiri (DB RCT)
7%
0.93 [0.32-2.69]
death
6/55
6/51
Kasiri (DB RCT)
7%
0.93 [0.32-2.69]
ventilation
6/55
6/51
Kasiri (DB RCT)
-24%
1.24 [0.57-2.69]
ICU
12/55
9/51
Kasiri (DB RCT)
28%
0.72 [0.29-1.79]
no recov.
7/55
9/51
Kasiri (DB RCT)
12%
0.88 [0.55-1.43]
no recov.
20/55
21/51
Kasiri (DB RCT)
14%
0.86 [0.73-1.01]
recov. time
55 (n)
51 (n)
Sunil Naik (RCT)
-169%
2.69 [0.11-64.6]
death
1/62
0/43
Sunil Naik (RCT)
-108%
2.08 [0.22-19.3]
progression
3/62
1/43
Sunil Naik (RCT)
7%
0.93 [0.82-1.04]
no recov.
62 (n)
43 (n)
Sunil Naik (RCT)
15%
0.85 [0.72-1.01]
no recov.
49/62
40/43
Sunil Naik (RCT)
24%
0.76 [0.60-0.95]
no recov.
62 (n)
43 (n)
COLSTAT
Shah (RCT)
-75%
1.75 [0.53-5.83]
death
7/125
4/125
CT2
COLSTAT
Shah (RCT)
-100%
2.00 [0.51-7.82]
death
6/125
3/125
CT2
COLSTAT
Shah (RCT)
-200%
3.00 [0.62-14.6]
ventilation
6/125
2/125
CT2
COLSTAT
Shah (RCT)
-46%
1.46 [0.76-2.83]
severe case
19/125
13/125
CT2
COLSTAT
Shah (RCT)
-73%
1.73 [0.86-3.48]
severe case
19/125
11/125
CT2
Villamañán
42%
0.58 [0.33-0.96]
death
19/111
32/111
Mehrizi
-13%
1.13 [1.08-1.19]
death
population-based cohort
Yadollahza.. (RCT)
33%
0.67 [0.28-1.60]
death
6/26
9/26
Vaziri (RCT)
81%
0.19 [0.04-0.88]
death
2/108
7/71
CT2
Vaziri (RCT)
89%
0.11 [0.01-0.89]
death
1/108
6/71
CT2
Vaziri (RCT)
87%
0.13 [0.03-0.58]
ICU
2/108
10/71
CT2
Vaziri (RCT)
35%
0.65 [0.58-0.73]
hosp. time
108 (n)
71 (n)
CT2
COLTREXONE
Gertner (RCT)
65%
0.35 [0.10-1.27]
ICU
67 (n)
70 (n)
COLTREXONE
Gertner (RCT)
43%
0.57 [0.27-1.20]
no recov.
67 (n)
70 (n)
COLTREXONE
Gertner (RCT)
24%
0.76 [0.55-1.10]
no recov.
67 (n)
70 (n)
COLTREXONE
Gertner (RCT)
34%
0.66 [0.28-1.53]
oxygen
67 (n)
70 (n)
COLTREXONE
Gertner (RCT)
20%
0.80 [0.59-1.07]
hosp. time
67 (n)
70 (n)
CONVINCE
Landi (RCT)
-4%
1.04 [0.06-16.6]
hosp.
30 (n)
29 (n)
CONVINCE
Landi (RCT)
-5%
1.05 [0.07-16.7]
oxygen
30 (n)
29 (n)
CONVINCE
Landi (RCT)
40%
0.60 [0.23-1.54]
misc.
30 (n)
29 (n)
CONVINCE
Landi (RCT)
11%
0.89 [0.41-1.93]
viral+
30 (n)
29 (n)
Madrid-García
-37%
1.37 [0.48-3.90]
death
n/a
n/a
Madrid-García
-137%
2.37 [0.64-8.73]
hosp.
n/a
n/a
Ozcifci
4%
0.96 [0.75-1.22]
cases
130/616
85/421
Monserrat .. (PSM)
80%
0.20 [0.02-0.93]
death
n/a
n/a
Topless
23%
0.77 [0.56-1.07]
death
population-based cohort
Oztas
-406%
5.06 [0.59-43.2]
hosp.
5/635
1/643
Oztas
-73%
1.73 [0.96-3.11]
symp. case
29/635
17/643
Oztas
-24%
1.24 [0.81-1.92]
cases
43/635
35/643
Avanoglu Guler
79%
0.21 [0.04-0.83]
oxygen
6/66
3/7
Correa-Rodríguez
-150%
2.50 [0.10-60.6]
oxygen
1/163
0/81
Correa-Rodríguez
-150%
2.50 [0.10-60.6]
hosp.
1/163
0/81
Correa-Rodríguez
7%
0.93 [0.51-1.70]
no recov.
13/24
7/12
Correa-Rodríguez
1%
0.99 [0.52-1.88]
cases
24/163
12/81
Sáenz-Aldea
-8%
1.08 [0.76-1.53]
hosp.
case control
Sáenz-Aldea
-12%
1.12 [0.91-1.37]
cases
case control
Chevalier
-28%
1.28 [0.51-2.35]
death
5/21
111/569
Chevalier
8%
0.92 [0.36-1.78]
hosp.
15/116
180/1,097
Colchicine COVID-19 outcomes
c19 early .org
October 2024
1 OT: comparison with other treatment 2 CT: study uses combined treatment
Favors colchicine
Favors control
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit